- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01252966
Cognitive Training for Nicotine Dependence
12. januar 2017 oppdatert av: University of Pennsylvania
This randomized clinical trial tested the effects of a computerized (web-based) cognitive training intervention on smoking cessation.
All participants received 8 weeks of standard nicotine patch therapy, smoking cessation counseling, and were randomized to 1 of 2 different training programs: cognitive training vs. control training.
Studieoversikt
Status
Fullført
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
213
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Center for Interdiscplinary Research on Nicotine Addiction, University of Pennsylvania
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 65 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion:
- Healthy male and female treatment-seeking smokers who are between 18 and 65 years of age and self-report smoking at least 5 cigarettes (menthol and/or non-menthol) per day for at least the last 6 months
- Plan to live in the area for at least the next 8 months
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form
- Able to communicate fluently in English (speaking, writing, and reading)
- Have uninterrupted access to a home computer with sound capabilities, keyboard, mouse, and active Internet connection
- Provide a Carbon Monoxide (CO) breath test reading greater than or equal to 8 parts per million (ppm) at Intake Visit
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Cognitive Training
Participants in this arm received computerized cognitive training in addition to nicotine patch and smoking cessation counseling.
|
The computerized cognitive training intervention is a 12-week standardized course of internet-based computerized cognitive exercises designed to enhance executive cognitive function.
|
|
Placebo komparator: Control Training
Participants in this arm received computerized control training in addition to nicotine patch and smoking cessation counseling
|
The computerized control training intervention is a 12-week standardized course of internet-based deep breathing exercises which does not contain the cognitive exercises designed to enhance executive cognitive function.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Point-prevalence Abstinence at End of Treatment
Tidsramme: End of treatment (Week 12)
|
Daily smoking, from the Target Quit Date to End of Treatment (EOT), was assessed by a validated timeline follow-back measure.
Based on guidelines for smoking cessation trials, the primary outcome was 7-day point prevalence abstinence at EOT, and abstinence was defined as no self-reported smoking (even a puff) for at least 7 days, with in-person verification by carbon monoxide breath levels (CO <8ppm).
Following standard convention, participants who withdrew or were lost to follow-up were considered smokers.
|
End of treatment (Week 12)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Point-prevalence Abstinence at 6-month Follow-up
Tidsramme: 6 month follow-up
|
Daily smoking from the Target Quit Date to 6 month follow-up was assessed by a validated timeline follow-back measure.
Based on guidelines for smoking cessation trials, the secondary outcome was 7-day point prevalence abstinence at the 6 month follow-up, and abstinence was defined as no self-reported smoking (even a puff) for at least 7 days, with in-person verification by carbon monoxide breath levels (CO <8ppm).
Following standard convention, participants who withdrew or were lost to follow-up were considered smokers.
|
6 month follow-up
|
|
Cognitive Performance (Working Memory)
Tidsramme: Baseline and Week 12 (EOT)
|
Change in performance on the Digit Span Forward task (working memory) between Baseline and End of Treatment (Week 12).
In this task, participants are presented with a series of digits on the computer screen at one second intervals.
Participants are then required to enter the digits in order.
The number of digits in each series ranges from 3 to 7, and the maximum recall span is the length of the largest series entered correctly.
The outcome measure is the change score (calculated by subtracting the Baseline score from the end of treatment score).
Change scores can range from -4 to 4. Negative numbers indicate worse performance at EOT; positive numbers indicate better performance at EOT; and 0 indicates no change.
|
Baseline and Week 12 (EOT)
|
|
Cognitive Performance (Response Inhibition)
Tidsramme: Baseline and Week 12 (EOT)
|
Change in performance on the Go/No-Go Task (response inhibition) between Baseline and End of Treatment (Week 12).
In this task, participants are presented with a series of stimuli (the word "PRESS" in either green or red).
Participants are instructed to respond by pressing the spacebar when the stimulus is green, and to withhold a response when the stimulus is red.
The outcome is the change in number of commission errors (failure to withhold a response to a red stimulus) from EOT minus baseline.
The potential range for the change score is -42 to 42.
Negative numbers indicate a decrease in the number of commission errors (improved performance) from baseline to EOT; positive numbers indicate an increase in commission errors (worse performance); 0 indicates no change.
|
Baseline and Week 12 (EOT)
|
|
Cognitive Performance (Attention)
Tidsramme: Baseline and Week 12 (EOT)
|
Change in performance on the Continuous Performance Task (attention) between Baseline and End of Treatment (Week 12).
In this task, participants are presented with a series of letters at 2.5s intervals and are instructed to respond by pressing the space bar if the same letter appears twice in a row.
The outcome is the change in the number of commission errors (the number of times the participant responded to a non-target at EOT minus baseline).
There are a total of 125 trials, with 20 target trials (response required) and 85 non-target trials (no response required); therefore the possible range for the change score is -85 to 85. Negative numbers indicate a decrease in commission errors (better performance at EOT compared to baseline); positive numbers indicate an increase in commission errors (worse performance at EOT compared to baseline); and 0 indicates no change.
|
Baseline and Week 12 (EOT)
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Caryn Lerman, PhD, University of Pennsylvania
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. mars 2011
Primær fullføring (Faktiske)
1. september 2015
Studiet fullført (Faktiske)
1. september 2015
Datoer for studieregistrering
Først innsendt
1. desember 2010
Først innsendt som oppfylte QC-kriteriene
1. desember 2010
Først lagt ut (Anslag)
3. desember 2010
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
16. januar 2017
Siste oppdatering sendt inn som oppfylte QC-kriteriene
12. januar 2017
Sist bekreftet
1. januar 2017
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 812429
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .